Fasting plasma glucose

Metabolic· appears in 400+ cited findings in this library

What it is and how the reviews use it

Fasting Plasma Glucose (FPG) is an endpoint used in regulatory review documents to measure the concentration of glucose in a patient's blood after a period of fasting. It serves as a key indicator in clinical trials, often appearing as a primary or secondary endpoint, to assess the efficacy of treatments for conditions like diabetes.

The regulatory reviews in this library frequently report FPG as a change from baseline. For instance, the Sanofi — Suliqua EMA EPAR public assessment report shows an FPG of -1.50 mmol/L. The Merck & Co., Inc. — Steglujan EMA EPAR public assessment report notes an FPG change from baseline vs Placebo of -46.05 mg/dL. Additionally, the Novo Nordisk A S — Ozempic EMA EPAR public assessment report indicates a Change in FPG at 56 weeks of -2.00 mmol/L.

Real examples — cited to the source page

Sanofi — Suliqua	FPG	-1.50	Suliqua EMA EPAR, p.72
Merck & Co., Inc. — Steglujan	FPG change from baseline vs Placebo	-46.05	Steglujan EMA EPAR, p.76
Merck & Co., Inc. — Steglatro	FPG change from baseline	-31.28	Steglatro EMA EPAR, p.66
Novo Nordisk A S — Awiqli	Fasting Plasma Glucose (FPG) reduction (comparator)	-1.87	Awiqli EMA EPAR, p.133
Novo Nordisk A S — Ozempic	Change in FPG at 56 weeks	-2.00	Ozempic EMA EPAR, p.69
ASTRAZENECA AB — Farxiga	FPG change from baseline (adjusted mean)	-4.1	Farxiga FDA Review, p.30
Boehringer Ingelheim — Synjardy	Mean baseline FPG	158.70	Synjardy EMA EPAR, p.21
NOVO — Rybelsus	Fasting Plasma Glucose Change from Baseline	-30.54	Rybelsus FDA Review, p.27

Different drugs were studied in different trials — these values are not head-to-head comparisons.

Explore the full evidence

Every Fasting finding in the library — searchable and answerable in plain language — is in the Metabolic research library →

Figures are as stated in the cited source documents. Educational reference only — not medical or investment advice.